BioHarvest Sciences (NASDAQ:BHST – Get Free Report) and Natural Alternatives International (NASDAQ:NAII – Get Free Report) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.
Risk & Volatility
BioHarvest Sciences has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.
Valuation and Earnings
This table compares BioHarvest Sciences and Natural Alternatives International”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioHarvest Sciences | $34.51 million | 1.03 | -$11.14 million | ($0.52) | -3.48 |
| Natural Alternatives International | $129.86 million | 0.10 | -$13.57 million | ($2.39) | -0.83 |
BioHarvest Sciences has higher earnings, but lower revenue than Natural Alternatives International. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Natural Alternatives International, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
32.4% of Natural Alternatives International shares are owned by institutional investors. 20.8% of Natural Alternatives International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for BioHarvest Sciences and Natural Alternatives International, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioHarvest Sciences | 1 | 0 | 2 | 0 | 2.33 |
| Natural Alternatives International | 1 | 0 | 0 | 0 | 1.00 |
BioHarvest Sciences presently has a consensus target price of $6.50, indicating a potential upside of 259.12%. Given BioHarvest Sciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe BioHarvest Sciences is more favorable than Natural Alternatives International.
Profitability
This table compares BioHarvest Sciences and Natural Alternatives International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioHarvest Sciences | -31.21% | -58.30% | -25.60% |
| Natural Alternatives International | -10.13% | -12.21% | -5.30% |
About BioHarvest Sciences
BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.
About Natural Alternatives International
Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
